TriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Meets Expectations

TriSalus Life Sciences (NASDAQ:TLSI) announced its earnings results on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35), Zacks reports. The business had revenue of $8.26 million for the quarter, compared to analysts’ expectations of $8.12 million. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Stock Up 2.2 %

TLSI opened at $5.62 on Friday. The company’s 50-day moving average price is $5.40 and its 200 day moving average price is $4.74. TriSalus Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $10.42. The firm has a market cap of $171.37 million, a price-to-earnings ratio of -2.26 and a beta of 0.48.

Insider Buying and Selling

In other news, CEO Mary T. Szela purchased 4,826 shares of the company’s stock in a transaction on Monday, January 27th. The shares were bought at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the purchase, the chief executive officer now owns 429,503 shares of the company’s stock, valued at $2,327,906.26. This trade represents a 1.14 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Emmett Young acquired 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was acquired at an average cost of $5.65 per share, with a total value of $33,900.00. Following the completion of the acquisition, the chief financial officer now directly owns 30,000 shares in the company, valued at approximately $169,500. This represents a 25.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 54,856 shares of company stock worth $294,608 in the last three months. 32.80% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on TLSI. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday. Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Roth Mkm reissued a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, TriSalus Life Sciences presently has an average rating of “Buy” and a consensus price target of $11.56.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.